抗疟药治疗不完全性狼疮研究(SMILE):随机对照试验方案
SMILE试验是一项随机双盲安慰剂对照研究,针对15-45岁、抗核抗体(ANA)≥1:80且符合2012年SLICC分类标准中1-2项其他标准的不完全性狼疮患者,比较羟氯喹与安慰剂治疗96周的效果。主要终点为SLICC标准下SLE特征数量的增加,次要终点包括进展为SLE分类的比例,并将评估眼科安全性及候选生物标志物。
要点
- 羟氯喹可能推迟SLE发病,但缺乏前瞻性验证。
- 研究对象为ANA≥1:80且SLICC标准1-2项的不完全性狼疮患者。
- 主要终点为SLICC标准下SLE特征数量增加。
核心结论
- SMILE试验将验证早期使用羟氯喹能否预防不完全性狼疮患者临床异常积累并调节定义SLE的免疫反应。
研究设计与样本
- 随机、双盲、安慰剂对照试验,比较羟氯喹与安慰剂。
- 纳入15-45岁、ANA≥1:80且符合2012年SLICC分类标准中1或2项其他标准的不完全性狼疮患者。
- 治疗阶段为96周。
关键数值与推荐
- 主要终点为2012年SLICC分类标准定义的SLE特征数量增加。
- 次要终点包括按SLICC标准进展为SLE分类的参与者比例。
临床怎么用
- 试验将评估该人群的眼科安全性。
- 研究将探索指导治疗决策的候选生物标志物。
- 将建立生物样本库供狼疮研究社区进一步机制研究。
局限性
- ANA试验广泛用于筛查SLE但特异性低,其意义解读具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Onset of systemic lupus erythematosus (SLE) is preceded by a preclinical phase characterized by expression of autoantibodies and nonspecific clinical symptoms. Hydroxychloroquine is a treatment for lupus that is widely used based on longstanding experience and a very good safety profile. Existing data suggest that treatment with hydroxychloroquine may postpone the onset of disease. However, prospective studies that prove and quantify the efficacy of hydroxychloroquine in the preclinical phase of lupus have not been done. This study will test the hypothesis that early hydroxychloroquine use can prevent accumulation of clinical abnormalities and modify immune responses that define SLE. METHODS: A randomized, double-blind, placebo-controlled trial of hydroxychloroquine vs placebo will be conducted. Participants will have incomplete lupus erythematosus as defined by the presence of antinuclear antibody (ANA) positivity at a titer of 1:80 or greater, as well as one or two additional criteria from the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. The age range will be 15-45 years and the treatment phase will be 96 weeks. The primary endpoint will be the increase in the number of features of SLE defined by the 2012 SLICC classification schema. Secondary outcomes will include the proportion of participants who transition to a classification of SLE as defined by SLICC criteria. DISCUSSION: A major challenge for improving therapies in patients with SLE is early detection of disease. The ANA test that is widely used to screen for SLE has low specificity and interpretation of its significance is challenging. The Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE) trial will provide insights into the appropriate target population for intervention, and will assess whether hydroxychloroquine can slow progression as measured by the accumulation of criteria. Ophthalmologic safety in this population will be assessed. The study will investigate candidate biomarkers that will guide treatment decisions and will accumulate a specimen biobank that will be available to the lupus research community for further in-depth mechanistic studies. This trial is a first step toward testing the feasibility of disease prevention strategies in SLE. TRIAL REGISTRATION: ClinicalTrials.gov, NCT 03030118 . Registered on 24 January 2017.
引用
- Olsen NJ, James JA, Arriens C, et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30572906. doi:10.1186/s13063-018-3076-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。